|
ZimultiAcompliaReport
|
 |
Your INDEPENDENT source of news about diet drug Acomplia / Zimulti (Rimonabant) | |||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
| What About ATL-962? |
|
What is ATL-962? ATL-962 is an inhibitor of gastrointestinal lipases designed to cause weight loss by reducing the digestion and thus the absorption of fat from the diet. Developed by the small British biotech company Alizyme plc, ATL-962 has a similar action to Roche's Xenical and preliminary data suggests that ATL-962 is about as effective as Xenical.. But ATL-962 has generated an interim phase IIb safety profile suggesting potential to minimize the incidence of adverse lower gastrointestinal effects -- oily spotting, fecal incontinence and flatus with discharge -- compared to Xenical. Alizyme in January entered into a licensing agreement with Takeda Chemical Industries, Ltd. of Japan, and the two companies announced that they intended to advance ATL-962 to phase III trials based on the phase IIb trial data. But phase III trials have yet to begin, and ATL-962 is not expected to be on the market-in Europe before 2007, and in the US and Japan before 2009. |
|
We subscribe to the HONcode principles of the HON Foundation. This is an independent news site reporting on rimonabant, a diet drug developed by Sanofi-Aventis Inc., which is marketing it in Europe under the trademarked name Acomplia and in the United States under the trademarked name Zimulti.. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.
(c) 2004-2006 Medical Week News, Inc. All Rights Reserved
Last Updated: 05/08/2007